Sanofi-Aventis (SNY-N)
NYSE:SNY
50.60
1.24
(2.39%) 1d
Financials
Technical Analysis
Buy, Sell or Hold?
Related posts
Top Covid-19 Vaccine Stocks to Bet on the Immunization Race (Updated)COVID-19 Stocks to Save Your RRSP + Forecasts and Facts (Updated)Battle of the Top Dividend ETFs : CanadaThis summary was created by AI, based on 3 opinions in the last 12 months.
Sanofi-Aventis (SNY-N) is highlighted as a 'TOP PICK' by multiple analysts, reflecting optimism regarding its growth trajectory. The company has reported sales growth exceeding 10% for three consecutive quarters, showcasing a robust financial performance. Analysts are particularly impressed with the strategic use of cash reserves for debt reduction and share buybacks, contributing to a strong return on equity (ROE) of around 25-27%. Valuations also appear favorable with the stock trading at 13-25 times earnings, indicating potential for price appreciation. The consensus price target suggests substantial upside potential in the coming months, underscoring confidence in the company's future prospects.
This french pharma company, developer of treatments for MS, myeloma and dermatitis (among many other products) is a TOP PICK. It trades at 25x earnings, under 2x book value and supports a 27% ROE. Cash reserves are being prudently used to reduce long term debt and the company is also buying back shares. We recommend setting a stop-loss at $42, looking to achieve $58 -- upside potential of 18%. Yield 4.2%
(Analysts’ price target is $57.50)SNY touched the bottom of its range in October 2023 on weak earnings and news that it would spin-off its consumer healthcare operations. The stock looks to be breaking out and while very hard to predict we think it is possible it trades in a higher new range. The drop last year was likely a one-off driven by the spin-off news, and barring a significant news item as such or consistently weak earnings, we would be surprised if it got back to the low-end of its range.
Unlock Premium - Try 5i Free
Sanofi-Aventis(SNY-N) Rating
Ranking : 4 out of 5
Bullish - Buy Signals / Votes : 1
Neutral - Hold Signals / Votes : 0
Bearish - Sell Signals / Votes : 0
Total Signals / Votes : 1
Sanofi-Aventis(SNY-N) Frequently Asked Questions
What is Sanofi-Aventis stock symbol?
Sanofi-Aventis is a American stock, trading under the symbol SNY-N on the New York Stock Exchange (SNY). It is usually referred to as NYSE:SNY or SNY-N
Is Sanofi-Aventis a buy or a sell?
In the last year, 1 stock analyst published opinions about SNY-N. 1 analyst recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Sanofi-Aventis.
Is Sanofi-Aventis a good investment or a top pick?
Sanofi-Aventis was recommended as a Top Pick by on . Read the latest stock experts ratings for Sanofi-Aventis.
Why is Sanofi-Aventis stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
Is Sanofi-Aventis worth watching?
1 stock analyst on Stockchase covered Sanofi-Aventis In the last year. It is a trending stock that is worth watching.
What is Sanofi-Aventis stock price?
On 2025-04-15, Sanofi-Aventis (SNY-N) stock closed at a price of $50.6.
We reiterate SNY as a TOP PICK. Recently reported earnings showed sales growth for the third consecutive quarter that exceeded 10%. Cash reserves are prudently being drawn down to retire debt and buy back shares. It trades at 13x earnings, 1.6x book and supports a 25% ROE. We recommend trailing up the stop (from $42) to $47, looking to achieve $64 -- upside potential of 20%. Yield 2.7%
(Analysts’ price target is $64.00)